Zdrowie i gospodarka · 07/11/2017
FDA Announces Guidance for Industry on Developing Direct-Acting Antiviral Drugs for Chronic Hepatitis C Treatment
The US Food and Drug Administration (FDA) has released a guidance document to help pharmaceutical companies develop direct-acting antiviral (DAA) drugs for treating chronic hepatitis C virus infection, finalizing a draft issued in 2016.